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ttp://dx.doi.org/10.1016/j.jmoldx.2012.09.004Circulating tumor cells (CTCs) are shed from cancerous tumors, enter the circulatory system, and migrate
to distant organs to form metastases that ultimately lead to the death of most patients with cancer.
Identiﬁcation and characterization of CTCs provides a means to study, monitor, and potentially interfere
with the metastatic process. Isolation of CTCs from blood is challenging because CTCs are rare and
possess characteristics that reﬂect the heterogeneity of cancers. Various methods have been developed
to enrich CTCs from many millions of normal blood cells. Microﬂuidics offers an opportunity to create
a next generation of superior CTC enrichment devices. This review focuses on various microﬂuidic
approaches that have been applied to date to capture CTCs from the blood of patients with cancer.
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products related to circulating tumor cells (CTCs).Circulating tumor cells (CTCs) are deﬁned as tumor cells in
the circulation. The dissemination of cancer cells from the
primary tumor is a ﬁrst step of the metastatic process in
distant organs and is the leading cause of death in patients
with cancer. Approximately 90% of patients with epithelial
cancers, accounting for approximately 80% of all cancers
throughout the world, die of metastatic disease rather than of
the direct effects of the primary tumor. An average tumor
may release an estimated million cells per day into the
bloodstream1; however, most dispersed cancer cells do not
survive. Nevertheless, the cells that do survive clearly pose
an existential threat to the host organism. From the moment
that CTCs were ﬁrst identiﬁed in 1869, an underlying
hypothesis has emerged that these cells originate from
primary tumors and perhaps from metastatic sites. For solid
tumors, the presence of these cells is evident late in disease
and is most apparent when metastatic disease sites are
already established. Identiﬁcation and characterization of
CTCs offers an opportunity to study, monitor, and, ulti-
mately, alter the metastatic process.
CTCs are exceedingly rare cells. Ordinary blood cell types
are present in tremendous numbers by comparison, and
patients with cancer may have altered levels of other blood
cell types to consider. These other cell types may comprise
leukocytes (approximately 7 million/mL of blood) and red
blood cells (approximately 5 billion/mL of blood). Assuming
that all CTCs shed from the primary tumor remain in thestigative Pathology
.circulatory system, an estimated yield of <200 CTCs/mL of
blood will be derived from an average male patient (5 L of
total blood volume). Therefore, CTCs should, theoretically,
be present at <0.004% of all mononucleated cells in the
blood. However, evidence thus far indicates that not all shed
CTCs remain in the circulation on comparison of CTC
numbers in blood near the site of primary tumor and periph-
eral blood.2 A working hypothesis is that these cells are in the
bloodstream for 24 hours.3,4 Further reports on the char-
acterization of blood constituents indicate that larger numbers
of cellular fragments are present in the circulatory system of
patients with cancer along with undamaged CTCs. Enumer-
ation of tumor cell fragments and intact CTCs can be used to
accurately predict the survival of patients with cancer.5
The life span and load of CTCsmay differ depending on the
type of their originating tumor and the current treatment
regimen. Ironically, surgical removal of the tumormay aid the
release of tumor cells into the circulation, thus facilitating the
process of metastasis. In fact, awareness of CTCs is causing
leading surgeons to modify their treatment routines to mini-
mize that possibility. Also, the ability of CTCs to interact with
other cell types, such as endothelial cells or platelets, may
Figure 1 CTCs and the metastatic process. A: A primary tumor may
release cells that enter into the bloodstream, becoming CTCs. B: Some
CTCs are damaged or destroyed in the circulation, leaving behind frag-
ments. C: Some CTCs may leave the bloodstream and can seed metastatic
lesions. D: In a metastatic tumor, cancer cells may evolve over time and
begin to exhibit characteristics different from the primary tumor. E: The
metastatic lesion may also release cells, introducing additional CTCs into
the bloodstream. F: CTCs from a metastatic lesion may repopulate the
primary site and even modify its characteristics. G: CTCs may also form
repositories in other locations, such as in bone marrow.
Dong et alaffect the number of CTCs in the circulation.4 Although the
study of CTCs is extremely challenging, their detection in the
circulation offers valuable information correlative with
patient prognosis.6
It is widely accepted that cells leave the evolving primary
tumor to perpetuate the metastatic process. However, recent
ﬁndings help to reﬁne thisworking hypothesis by demonstrating
that tumor cells from metastatic sites and the blood can repo-
pulate the primary site and modify characteristics of even
primary tumors.7 Another reason for CTC monitoring is
underscored by cases where the primary tumor (prostate or
breast cancer, for example) is often completely excised or does
not persist throughout the disease. Nevertheless, such patients
may acquiremetastatic events from dormant reservoirs of tumor
cells elsewhere, such as in the bone marrow (Figure 1). There-
fore, routine and sensitive monitoring of CTCs may be of
tremendous value for early detection of recurrent disease and is
possibly the only means to gain dynamic molecular character-
ization of tumor cells in the midst of advancing disease status.
A primary tumor contains a heterogeneous cell population
composed of tumor cells, normal tissue supporting stroma
and endothelium, and inﬂammatory cells. All contribute to
the rapid expansion in size, vascularization capacity, genetic
instability, nutrient deprivation, normoxia and hypoxia, re-
programming, necrosis, and shedding. Consistent with these
observations, one may expect CTCs to be heterogeneous as
well. Indeed, considerable evidence exists that subpopulations
of these cells may be destined for selected sites in tumor
progression and metastasis.8,9 A minority of CTCs actually
foster new tumors. Thus, the metastatic potential of those true
tumor-initiating cells is likely to vary depending on a patient’s
genetics, disease status, and treatment history. The ability to
monitor various CTCs may require a complex set of isolation
approaches and speciﬁc characterization markers.Principles and Requirements for CTC Isolation
from Blood
The ultimate goal of any CTC detection technology is to
identify cells that are capable of forming distant metastases.
However, the characteristics of such CTCs are currently not
clear. In addition, it is likely that those features will be
unique to different cancers because it is well-known that
certain cancers metastasize to speciﬁc sites. Therefore, it is
conceivable that a speciﬁc approach has to be optimized for
each speciﬁc tumor type. Nevertheless, any CTC detection
technology has to be capable of detecting very low numbers
of tumor cells in a background of millions of blood cells.
For example, 57% of 123 tested patients with metastatic
prostate cancer had two or more CTCs per 7.5 mL of blood;
however, only 32% of these patients had 10 CTCs per
milliliter.10 To capture sufﬁcient numbers of CTCs in
a broad number of patients for statistically reliable and
reproducible diagnostic applications, it is likely that large
volumes of blood (20 mL) will have to be processed.150Most CTC enrichment and detection technologies use
one or more unique properties of CTCs that distinguish
them from the surrounding normal blood cells: biological
properties (surface protein expression, presence of muta-
tions, expression of speciﬁc genes, viability, and invasion
capacity) and/or physical properties (size, density, electrical
charges, and deformability). It is important to note that most
of the current technologies that rely on isolating CTCs based
on biological properties are based on epithelial cell adhesion
molecule (EpCAM), a protein marker expressed on the
surface of cells of epithelial origin. However, the process of
tumor cell dissemination may be accompanied by the loss
or signiﬁcant reduction of EpCAM expression, therefore
rendering EpCAM-based CTC capture technologies useless
in capturing EpCAM-negative CTCs. These cells may be of
great importance in the metastatic process.
The second most frequent approach is to isolate CTCs
using the fact that most but not all of the tumor cells in the
circulation are larger than most blood cells. It was reported
that the size of captured tumor cells varies over a wide range
from >4 to <30 mm, even in cells from a single patient.10
Therefore, ﬁnely tuned ﬁlters can be manufactured that
retain only tumor cells and let most of the blood cells go
through. Although ﬁlter-based approaches are not limited by
speciﬁc biological properties of cells, they are less likely to
capture cells similar in size to blood cells. Filter-based
approaches will also be unable to capture clinicallyjmd.amjpathol.org - The Journal of Molecular Diagnostics
Microﬂuidics and CTCsinformative tumor cell fragments. After capture, identiﬁcation
of tumor cells is mostly accomplished by staining cancer cells
with speciﬁc markers that distinguish these cells from blood
cells that are falsely co-captured alongwith CTCs, a challenge
encountered by all existing CTC-capturing technologies.
Overview of Microﬂuidic Methods for CTC
Capture
Microﬂuidic methods are an effective means to interrogate
the constituents of biological ﬂuids for diagnostic purposes,
just as they are useful for precise measurements and assays
for other analytical processes, such as drug screening, nucleic
acid ampliﬁcation, and enzymatic reactions. Microﬂuidic
methods naturally lend themselves to solving the problem
of capturing rare cells because device performance can be
tailored to exploit physical and/or biological differences
between CTCs and the background cells, enabling isolation. In
addition, microﬂuidic approaches allow for gentle capturing of
live rare cells so that further analysis can be performed using
cellular, microscopic, or molecular techniques. Furthermore,Table 1 Summary of Microﬂuidics-Based Approaches for the Capture
CTC properties used Strategy
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The Journal of Molecular Diagnostics - jmd.amjpathol.orgmicroﬂuidics presents an opportunity to combine isolation and
detection methods in a single device, opening the door for the
development of true point-of-care diagnostic CTC devices. A
tradeoff of microﬂuidics is the challenge of analyzing large
sample volumes to access key information about rare cells in
the circulation. The small dimensional features of chip design
and complex ﬂuid dynamics can interfere with efﬁcient, large-
scale capture of speciﬁc, rare cells unless its format and
microﬂuidics are styled to meet those speciﬁc requirements. In
the following section, we review the microﬂuidic approaches
to CTC isolation that have been described to date (summarized
in Table 1).Microﬂuidic Isolation Based on Differential
Physical Properties of CTCs
Size-Based Filtration
Because tumor cell diameter tends to be larger than that of
normal blood cells,29 several microﬂuidic systems have been
developed to isolate CTCs by virtue of their increased relativeof CTCs
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Dong et alsize. The fabrication techniques used to design and construct
microﬂuidic devices allow for control of device properties at the
micrometer scale, so these devices naturally lend themselves to
assays in which size-based ﬁltration is used to separate cells.
Microﬂuidic size-based CTC capture systems aim to achieve
superior results compared with macrosize-based approaches,
such as ﬁlter membranes. Mohamed et al11 designed a micro-
machined device of arrays of four successively narrower
channels to isolate cells from eight tumor cell lines. Their
devices have channels ranging from 20 to 5 mm in width and
depth. The 20-mm segment was used to disperse samples evenly
across the chip. The subsequent segments were used to trap
increasingly smaller cells. Spacing between microchannels was
carefully designed to prevent clogging of the chip.
Often, microﬂuidics is used to complement traditional
size-based CTC selection methods. Tan et al12,30 designed
a device with multiple arrays of crescent-shaped isolation
wells that achieved CTC isolation by size and deformability
differences between CTCs and white blood cells. Each well
consists of three pillars with 5-mmgaps in between that ensure
efﬁcient CTC trappingwhile allowingmore deformable white
blood cells to be removed. Using microelectromechanical
systemebased technology and a membrane ﬁlter, Zheng
et al13 integrated CTC isolation and on-chip cell lysis for
PCR-based genomic analysis. A parylene membrane micro-
ﬁlter was used in this case for cell enrichment. An array of
microelectrodes was built with microfabrication processes to
address each individual pore. Once CTCs were captured, on-
membrane electrolysis was performed to lyse cells and allow
for subsequent PCR analysis on the CTCs.
One concern for size-based capture is that its efﬁciency may
be undermined by heterogeneous CTC size in patient blood.
Selection of a size cutoff may yield reliable CTC isolation in
most of the patient samples but inadequate performance across
all patients. In addition, cells are deformable, and if the oper-
ating conditions are not carefully controlled, passage through
small openings may cause shear stress and potential damage to
or loss of the CTCs. Determining the optimum cutoff size
involves considerations such as the range in viscosities of
patient samples and the desired throughput. The clinical use-
fulness of these approaches remains to be validated.
Size-Based Streamline Sorting
Streamline sorting is an alternative means of size-based
ﬁltration in which cells of different sizes migrate into unique
streamlines based on ﬂuid forces. After separation into
streamlines has taken place, the bulk ﬂow is segmented to
collect these streamlines at different outputs. The advantage
is that the cells do not pass through any physical constric-
tions, so shear forces are reduced. In addition, these devices
typically operate at relatively high ﬂow rates, resulting in
high throughput. However, to enable sorting, the ﬂuid forces
in the device have to be precisely controlled, often requiring
that the patient sample be diluted with a carrier liquid of
known properties. This enables the device to function152equally, regardless of the properties of the patient sample;
however, only a relatively small sample volume can be
handled at a time, and enrichment efﬁciency is limited.15
Yamada and colleagues14,31,32 proposed a series of size- and
shape-based cell-sorting microdevices, including pinch ﬂow
fractionation and hydrodynamic ﬁltration. The central idea
of these technologies is based on the fact that at a low Reyn-
olds number (a measure of the ratio of inertial forces to viscous
forces), the center of a particle will follow streamlines. By
controlling ﬂow rates through one or more inlets and opti-
mizing asymmetrical channel geometry, cells of different sizes
and shapes will move along different streamlines in the ﬂow.
With carefully positioned or conﬁgured outlets, cells of dif-
ferent sizes and shapesmove into corresponding outlets and are
separated.
Di Carlo and coworkers33,34 demonstrated that ﬂowing
particles also migrate across streamlines in microchannels
experiencing laminar ﬂow, consistent with observations
made some 100 years ago by Hele-Shaw. The shear gradient
lift force tends to push particles toward the wall, and the wall
effect lift force pushes particles toward the center of
the channel. When the particle size is comparable with the
channel dimension, these lift forces are signiﬁcant and lead to
lateral migration across ﬂow streamlines. By biasing the
balance of the two lift forces, cells migrate to distinct vertical
and lateral equilibrium positions in the channel. Thus,
different cells are focused at different locations. In addition,
expanding the microchannel quickly in width can generate
microvortices. In the expansion region, the wall effect lift is
not signiﬁcant as the neighboring channel wall is no longer
within its vicinity. The shear gradient lift force dominates and
drives cells across streamlines toward the center of the
vortices. Cells above a critical size enter the vortex and
maintain a stable position in the vortex. With this system,
they were able to concentrate 10 mL of blood with 500 spiked
cancer cells to 200 mL within 3 minutes. They recovered
a mean SD of 102 21 cancer cells with 221 155 blood
cells. Although the w20% recovery rate is low, the 40%
purity achieved is higher than that in most reported processes.
Bhagat et al16 used lift forceeinduced cell separation
combined with size constriction to isolate spiked cancer cells
in blood. The microchannel design of this device consists
of three regions in sequential order: focused volumetric
ﬂow, size-based constriction, and cell-isolating regions. The
focusing and constriction regions are high aspect ratio rect-
angular channels patternedwith contraction-expansion arrays.
The focusing region consists of 70 contraction-expansion
subunits and has a 20-mm width at the contraction parts of
the channel. All cells migrating through this region equilibrate
efﬁciently along the channel sidewalls under the inﬂuence of
shear-modulated inertial lift force. The constriction region
consists of ﬁve contraction-expansion subunits. Here, the
width at the contracted parts of the channel is smaller than the
average size of cancer cells. Larger cancer cells enter con-
stricted pinch points in the narrower channel, and normal
blood cells remain aligned along the channel sidewalls. Thejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Examples of CTC capture technologies that combine multiple
enrichment principles. A: The DEP ﬁeld-ﬂow fractionation device developed by
Gascoyne and colleagues18 combines the use of hydrodynamic lift, sedimenta-
tion, and DEP to capture cancer cells on the surface of the microelectrode array.
B: The dual-capture microﬂuidic chip developed by On-Q-ity Inc. combines
immuno- and size-based approaches to capture CTCs from the unfractionated
blood of patients with cancer.28 Cancer cells ﬂowing through the chips interact
with a carefully positioned gradient array of antibody-coated microposts. Cells
and cellular fragments that have targeted antigens on their surface are captured
via interaction with immobilized antibody (mostly near the inlet of the chip).
Cancer cells that do not express targeted antigens are captured in the area of the
chip where their diameter exceeds a distance between neighboring microposts
(approximately 10 mm), near the outlet of the chip.
Microﬂuidics and CTCsisolating region of bifurcating outlets allows cancer cells to
be isolated at the center outlet and normal blood cells to be
removed from the side outlets. As the presence of CTCs in
the constricting region disturbs the ﬂow ﬁeld in its immediate
vicinity, a fraction of normal blood cells are collected at
the center outlet, which lowers the enrichment efﬁciency. The
reiterative design incorporated adding central ﬂow through
a second identical device. With this improvement, the inves-
tigators were able to achieve 81% CTC recovery, with 3.25
105efold enrichment over red blood cells and 1.2 104efold
enrichment over leukocytes. The process required a 20
sample dilution, but the high ﬂow rate of w400 mL/min
allowed the processing ofw108 cells/min.
DEP Separation
Dielectrophoresis (DEP) is a separation technique based on
differences in particle polarizability and size. When electrical
ﬁelds are applied to particles, they become polarized. This
induced polarization, in turn, interacts with the applied ﬁeld,
resulting in each particle experiencing a unique net electrical
force. The magnitude of this net force depends on the
dielectric characteristics of the particles (how big the cells are
and how easily they are polarized), the frequency and
strength of the electrical ﬁeld, and the electrical properties of
the ﬂuid medium. DEP forces can be used in two formats for
separation: DEP migration, where different types of particles
migrate to different regions based on their relative polariz-
ability, and DEP retention, where DEP forces are used in
competition with ﬂuid ﬂow forces. In this case, particles
experiencing a negative or small positive DEP force are
eluted by the ﬂow, whereas particles experiencing a strong
positive DEP force are retained at the electrode edges. In the
case of CTC isolation from blood, electrophoretic mobility
distinguishes tumor cells with attraction toward the electrode,
and normal blood cells migrate in the electrical ﬁeld into
eluant. Becker et al17 proved the feasibility of separating
human breast cancer cells from blood using DEP retention.
However, traditional DEP migration and retention methods
rely on relatively large dielectric differences and do not have
enough resolution for efﬁcient isolation of CTCs owing to
smaller dielectric differences from leukocytes.
Gascoyne and colleagues18,35 illustrated CTC isolation
using dielectrophoretic, gravitational, and hydrodynamic lift
forces in combination by constructing a thin DEP microﬂuidic
chamber with a laminar ﬂow proﬁle (Figure 2A). Spiked
cultured cell lines move faster near the center of the laminar
ﬂow, resulting in velocity gradient. The DEP array pulls tumor
cells toward the edge of the electrode and leaves smaller cells
closer to the center. The tumor cells travel slowly near the
edge, whereas normal blood cells travel quickly near the center
and get carried away by the ﬂow. In a 5-mL chamber, they
were able to achieve 92% CTC recovery from a 10% chamber
load. Recovery decreased quickly when the chamber load was
increased. Higher recovery efﬁciencies can be achieved from
larger blood volumes by scaling up the chamber size, althoughThe Journal of Molecular Diagnostics - jmd.amjpathol.orgincreased processing time also was shown to have detrimental
effects on capture efﬁciency.
DEP approaches are attractive in that larger volumes of
patient samples can be treated in ﬂow-throughestyle devices,
but the device’s rely on a consistent ﬂuid medium for
reproducible polarizing of cells, necessitating the sample to
be diluted before operation. Similar to the streamline-based
sorting techniques, the required dilution can limit throughput
and enrichment of CTCs.
To enhance the effectiveness of DEP for the isolation of
CTCs, the collaborators on the MIRACLE project rely on the
use of antibody-coated magnetic nanoparticles to apply
a known polarity to CTCs. When the pretreated blood is
passed through their cell isolation module, DEP-inﬂuenced
ﬂuid ﬂow dynamics serve to sort cell-nanoparticle complexes
into one outlet and unbound nanoparticles into another. The
enriched sample is further processed through downstream
modules for CTC enumeration, reverse transcription multi-
plex ligationedependent probe ampliﬁcation, and electro-
chemical gene detection, demonstrating the potential for
future integrated lab-on-a-chip solutions.26
Microﬂuidic CTC Isolation Based on Binding of
Cell Surface Markers
CTCs can also be distinguished from background cells based
on their surface markers. The small size of microﬂuidic153
Dong et alfeatures and channels (on the same scale as the cell)
allows for creation of devices that have extraordinarily
high relative surface area. The large surface area is coated
with ligands or capture molecules that bind to the surface
markers of CTCs. Often, well-characterized antibody-
antigen pairs, such as anti-EpCAM and EpCAM, are
used.36e38 When CTCs ﬂow across the device, the interac-
tion between these binding ligands and CTC surface markers
can capture and retain the cells, and the remaining blood
components are carried away by the ﬂow. The large surface
area allows for many possible interaction sites to increase
the chances of CTC capture.
The challenge of afﬁnity-based isolation is to facilitate
strong interactions between cells and the surface-bound
capture molecules. This requires optimization of antibody
immobilization processes, along with creating optimal
opportunities for interaction between the antibody and the
antigen. The typical dissociation constant of an antibody
bound to antigen ranges from 1010 to 109 mol/L, but
when the antibody is immobilized on a surface, the disso-
ciation constant drops to approximately 107 mol/L.36 This
close to 1000-fold drop in afﬁnity is believed to be the result
of denaturation of the three-dimensional structure1,19 of the
protein and steric hindrance of antigen-recognition sites.20
In microﬂuidic devices, denaturation is the result of a
biofouling property of the device surface and can be alle-
viated by coating the surface with hydrophilic materials.
Steric hindrance is the result of poor orientation of the
immobilized antibody and the short distance between the
antibody and the surface. The large size of an intact CTC
(at 10 mm) relative to individual antibody molecules further
compounds the technical challenges faced by the developer.
A common way of improving antibody orientation and
presentation to the CTC is to coat the surface with avidin
and then immobilize a biotinylated antibody. Optimized
surface chemistries using avidin-biotin antibody conjugation
to the chip in addition to polymers such as dextran of
varying composition and size (40,000 to 200,000 Da) are
used to extend the immobilized antibody away from the
surface and further improve afﬁnity.
Afﬁnity-based capture is also affected by the design of
the microﬂuidic chip and the resulting ﬂow of the CTCs past
the antibody surface. It is known that in laminar ﬂow, which
is typical in microﬂuidic devices, a nanoscale hydrodynamic
lubrication layer exists close to the surface. This is typically
neglected for protein or DNA analysis owing to each dis-
playing small macromolecular size (relative to an intact
whole cell or cell fragment) and high diffusion coefﬁcients.
Cells, however, are signiﬁcantly larger (lymphocytes are
usually 5 mm in diameter and CTCs >10 mm) and do not
easily migrate from their streamlines unless other forces,
such as those discussed in the previous sections, are present.
This lubrication layer retards the movement of cells toward
the microﬂuidic device surface and can signiﬁcantly hinder
the binding interactions between CTCs and surface-bound
antibodies. The solution is to adjust or add additional154microﬂuidic features that facilitate cell-speciﬁc interaction
with surfaces such as the aforementioned EpCAM-antibody
conjugation so that CTC capture can take place.
Afﬁnity-based capture is further complicated by the
possibility of nonspeciﬁc capture. Flow rates have to be
optimized to balance two counteracting factors when pro-
cessing the sample: the ﬂow rate has to be slow enough to
ensure maximum cell-surface attachment but reasonably
fast to generate enough shear force to prevent nonspeciﬁc
attachment of blood cells to the surface. All the previously
mentioned challenges to afﬁnity capture must be consid-
ered when designing a microﬂuidic capture device. In the
following paragraphs, we discuss various successful ap-
proaches to afﬁnity-based CTC capture.
Nagrath et al38 designed the CTC-chip in an attempt to
solve these problems. Their CTC-chip is a silicon chamber
etched with 78,000 microposts in staggered arrangement
with 50-mm spacing. The posts are coated with anti-EpCAM
antibodies. The ﬂow kinetics is optimized for minimal
shear stress on cells. The beneﬁts of this postarray are
twofold. First, it creates a device with an incredibly large
antibody-coated surface area, providing many sites for CTC
capture. Second, and more important, these posts stand in
the ﬂow path and counter the negative impact of the lubri-
cation layer to enhance cell-surface interaction for CTC
capture. In addition, the captured cells are ﬁxed on the
micropost, which allows nonspeciﬁcally bound leukocytes
to be washed out. As a result, a 106-fold enrichment of
CTCs against leukocytes was achieved.
Hughes and King21 coated halloysite nanotubes onto the
inner surface of a microtube CTC capture device. The hal-
loysite nanotubes were used to present selectin, the capture
molecule in this study, to the ﬂow. Such a design has two
beneﬁts: ﬁrst, halloysite nanotubes increased the surface area
and doubled protein deposition inside the device; second,
these nanotubes were found to extend into the ﬂow ﬁeld,
better presenting selectin molecules for interaction with cells.
Wang et al22 used antibody-coated silicon nanopillar
arrays to recover CTCs from blood. The nanopillar array was
generated on silicon wafers with pillar height ofw10 mm and
pillar diameter of 100 to 200 nm. Biotin-streptavidin conju-
gation was used to immobilize EpCAM antibodies on the
silicon nanopillar substrate. In addition to the increased
surface area and diminished lubrication layer provided by
the nanopillar array, this approach also demonstrated that
substrate topography can inﬂuence cellular behavior such as
cell adhesion. The combined effects of these three improve-
ments resulted in a ﬁvefold higher CTC recovery rate
compared with that on ﬂat substrate.
Another way of enhancing cell-surface interaction is
demonstrated in the microvortex-generating herringbone
chip by Stott et al.39 The herringbone chip design was
inspired by a chaotic mixer for microchannels developed by
Stroock et al40,41 to overcome the slow diffusion of mole-
cules and particles perpendicular to the direction of typical
laminar ﬂow in most microﬂuidic devices. The chaoticjmd.amjpathol.org - The Journal of Molecular Diagnostics
Microﬂuidics and CTCsmixers are essentially a series of grooves designed in
such a way that they passively generate turbulent ﬂows in
the channel and mix solutions much more efﬁciently than
a simple, smooth channel. Stott et al39 extended this prin-
ciple and developed the herringbone chip that integrated
a grooved microvortex mixer with a ﬂat substrate. With
optimized geometry design and ﬂow conditions, the cells
were driven into contact with the antibody-coated grooved
walls of the device, where afﬁnity-based capture of CTCs
took place. The result is a 92% recovery rate in spiked
cancer cell samples compared with approximately 60% in
the CTC-chip. Wang et al23 also used chaotic micromixers
integrated into their silicon nanopillar substrate and improved
their recovery in spiked sample from 45% to 65% to 95%.
Recently, Mittal et al24 demonstrated the use of a ﬂuid-
permeable surface to promote cell rolling for enhanced
CTC capture. The device consists of an anti-EpCAMe
coated polycarbonate membrane sandwiched between two
polydimethylsiloxane ﬂow chambers. The membrane has
200-nm-diameter pores that allow ﬂuid permeation but that
are small enough to prevent cells from entering. When ﬂow
conditions are optimized, this device can encourage the
mass movement of cells toward the porous surface and
promote cell-surface interaction through dynamic rolling
adhesion of cells with high speciﬁcity. The major beneﬁt of
this device is the signiﬁcantly improved throughput. High
cell recovery can be achieved at ﬂow rates 20 times higher
than comparable devices with solid surfaces.
The beneﬁts of porous substrate materials were also
adapted to micropost designs comparable with the CTC-chip.
Similar to the lubrication layers near a ﬂat surface of a channel
wall, the boundary layers at the liquid-solid post interface
can prevent microparticles, such as cells, from contacting
the solid surface, resulting in poor recovery. Chen et al25
compared particle and bacteria capture on solid and porous
micropost arrays with the same overall post diameter and chip
geometry. The solid post is made of polydimethylsiloxane,
and the porous post is made of patterned carbon nanotube
forests. The porous post array yields an average of six times
higher recovery of spiked bioparticles. This improvement
was attributed to diminishing the boundary layers at the ﬂuid-
solid layer interaction allowed for by the porous post
materials.Microﬂuidic CTC Isolation Based on Physical
Property Differences and Binding of Surface
Markers
As mentioned previously herein, CTC populations are highly
heterogonous in physical (size) and biological (expression
level of surface antigens) properties. This limits the utility of
CTC capture approaches that rely on a single isolation
approach. However, the possibility exists to improve re-
covery efﬁciency by combining several capture approaches in
the same device.The Journal of Molecular Diagnostics - jmd.amjpathol.orgEphesia is a technology that combines microﬂuidic cell
sorting and immunomagnetic sorting. First, a hexagonal
array of magnetic ink is applied to the bottom surface of
the microﬂuidic ﬂow chamber using microcontact printing.
Then, antibody-coated magnetic microbeads are injected.
When a vertical magnetic ﬁeld is applied to the device,
magnetic beads align to nearby magnetic ink patches and
self-assemble into an array of bead pillars. The cell-antibody
interaction takes place in similar hydrodynamic conditions
as the CTC-chip and yields comparable CTC recovery. The
pillar can be disassembled by removing the magnetic ﬁeld,
which is advantageous for the retrieval and downstream
biological analysis of the enriched CTCs. Another beneﬁt of
this approach is that the microbead pillars are comparable
with silicon pillars (high aspect ratio, 50 mm high and
4.5 mm in diameter) and are easily manufactured without
resorting to specialized fabrication techniques. In addition,
the bead functionalization process is well understood and
takes place off-chip, allowing for large-batch preparation
and use of storage solutions to keep the functionalized beads
stable. This makes further development and quality control
relatively easier.27
Dharmasiri et al28 developed a device called a high-
throughput microsampling unit, which integrates afﬁnity
capture of CTCs from blood and subsequent electrokinetic
enrichment to screen out false-positive cells from the
afﬁnity capture step. The ﬁrst part of the device consists of
high aspect ratio (150  35 mm) sinusoidal channels coated
with anti-EpCAM. To increase throughput, 51 channels are
cast in parallel with a common inlet and outlet. In these
channels, CTCs are captured by afﬁnity and then released
with trypsin infusion. The released cells ﬂow through
a conductivity sensor for enumeration and are transported to
the electrokinetic manipulation region of the device, where
CTCs are further concentrated via electromigration. The
CTCs are collected in a 2-mL ﬁnal volume and are searched
for point mutations using PCR, ligase detection reaction,
and electrophoresis assays.
The On-Q-ity C5 chip (On-Q-ity Inc., Waltham, MA) is
an advanced micropillar array using a combination of
antibody afﬁnity capture and size capture on a single chip
(Figure 2B). Small clusters of antibody-coated pillar sub-
arrays are carefully spaced to minimize local stress experi-
enced by individual CTCs while ensuring high overall ﬂow.
By limiting such shear stress, enhanced cell-surface inter-
actions occur, facilitating antibody capture and limiting
potential damage to the cells. The high overall ﬂow rate
maintains high process throughput and reduces nonspeciﬁc
blood cell capture. Addition of a crosslinker is used to
spatially extend the antibody into the ﬂow, thus facilitating
interaction between antibodies and their antigens while
limiting potentially damaging interaction of the cell with
the physical chip surface. The surface chemistry was also
developed to allow gentle enzymatic release of surface-
bound CTCs after capture. In addition, this device contains
a size-dominated capture region to capture CTCs (with gap155
Dong et alsizes tapering from 20 mm) to allow for ﬂow of the smaller
lymphocytes while capturing the larger CTCs. This region
of the chip generally is prone to sequestering cells with low
or no expression of the surface markers without imposing
signiﬁcant shear stress on these captured cells. When coated
with anti-EpCam antibodies, the C5 chip demonstrated
efﬁcient capture of a variety of EpCam-positive and EpCam-
negative cells (80% to 100% capture efﬁciency from up to
20 mL of unprocessed blood).42Discussion
Despite the fact that CTCs were ﬁrst described >100 years
ago, there is still limited understanding of the exact role
that these cells play in the metastatic process. Such lack
of clarity can be attributed to the fact that CTCs are rare in
blood relative to normal blood cells. In vivo observation of
CTCs is nearly impossible. Heterogeneity of CTCs makes
isolation and characterization of CTCs difﬁcult as well.
Nevertheless, the obvious importance of CTCs in the me-
tastatic process, and the potential of using those cells for
noninvasive cancer detection, characterization, and moni-
toring encourages the efforts to develop robust, reproducible
CTC capture and characterization approaches that will be
widely used in research and clinical settings.
In this review, we focused on the utility of microﬂuidic
systems for the capture of CTCs using a variety of CTC
capture strategies. Many approaches gauge performance
against CellSearch (Veridex LLC, Raritan, NJ), the only
Food and Drug Administrationeapproved device for CTC
detection. The CellSearch system, the current industry
standard, uses EpCAM-coated immunomagnetic particles
to capture and align CTCs for subsequent microscopic
analysis. Although CellSearch comparisons are frequently
performed and reported, different markers are often used to
identify CTCs, making the comparison difﬁcult to inter-
pret. It is well-known that even variant clones of antibodies
directed against the same protein will display different
speciﬁcities. The possibility of developing a standardized
CTC control kit was raised to facilitate objective com-
parison between CTC platforms, but until such a kit is
available, critical evaluation of the platforms remains
challenging.
Owing to the heterogeneity of CTCs, it is likely that
hybrid strategies (strategies that rely on more than one
principle for CTC capture) will be more robust. Indeed, our
own studies have indicated that strategies that use hybrid
approaches hold distinct advantages in capturing increasing
numbers of CTCs without conferring detrimental effects on
speciﬁcity in head and neck and prostate cancer (Y. Dong,
K.M. Sprott, C. Jiang, D.A. Smirnov, and W.P. Carney,
unpublished data). However, it is difﬁcult to comparatively
evaluate CTC enrichment platforms. Often, performance of
each platform is presented as the sensitivity of a platform in
a given population of patients with cancer but less often is156speciﬁcity reported as well. Even if the average number
of cells recovered per patient is reported, interpretation of
such performance metrics is difﬁcult because of the de-
pendence on the population of patients with cancer tested. A
greater share of patients with advanced progressing disease
will increase the sensitivity of the platform.
Ultimately, routine detection and characterization of
CTCs will be clinically useful only if it provides physi-
cians with unique information that helps make choice-of-
treatment decisions. This is a challenge faced by the CTC
ﬁeld regardless of whether microﬂuidics is used for CTC
capture. However, as we have seen, microﬂuidics has
facilitated the development of many innovative and ﬂexible
research systems that can capture CTCs at increasingly
higher yields and facilitate all manners of downstream
characterization. Some of these microﬂuidic systems have
already begun to gain entry into a variety of clinical trials.
As these systems continue to be improved and validated, we
believe that microﬂuidics will play a signiﬁcant role in
promoting the study of CTCs and advancing the race toward
achieving clinical relevance.
References
1. Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J,
Brown WR, Cantarero LA: The physical and functional behavior of
capture antibodies adsorbed on polystyrene. J Immunol Methods 1992,
150:77e90
2. Okumura Y, Tanaka F, Yoneda K, Hashimoto M, Takuwa T,
Kondo N, Hasegawa S: Circulating tumor cells in pulmonary venous
blood of primary lung cancer patients. Ann Thoracic Surg 2009, 87:
1669e1675
3. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L,
Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL,
Tsukrov DI, Kempner ME, Dahl DM, Wu C-L, Iafrate AJ, Smith MR,
Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S:
Isolation and characterization of circulating tumor cells from patients
with localized and metastatic prostate cancer. Sci Transl Med 2010, 2:
25ra23
4. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF,
Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L,
Fleming TP, Herlyn D, Terstappen LWMM, Fehm T, Tucker TF,
Lane N, Wang J, Uhr JW: Circulating tumor cells in patients with
breast cancer dormancy. Clin Cancer Res 2004, 10:8152e8162
5. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW: All
circulating EpCAMþCKþCD45- objects predict overall survival in
castration-resistant prostate cancer. Ann Oncol 2010, 21:1851e1857
6. Van De Stolpe A, Pantel K, Sleijfer S, Terstappen LW, Den
Toonder JMJ: Circulating tumor cell isolation and diagnostics: toward
routine clinical use. Cancer Res 2011, 71:5955e5960
7. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH-F,
Norton L, Massagué J: Tumor self-seeding by circulating cancer cells.
Cell 2009, 139:1315e1326
8. Norton L, Massague J: Is cancer a disease of self-seeding? Nat Med
2006, 12:875e878
9. Attard G, Swennenhuis JF, Olmos D, Reid AHM, Vickers E,
A’Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB,
Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP,
Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME,
Terstappen LW, de Bono JS: Characterization of ERG, AR and PTEN
gene status in circulating tumor cells from patients with castration-
resistant prostate cancer. Cancer Res 2009, 69:2912e2918jmd.amjpathol.org - The Journal of Molecular Diagnostics
Microﬂuidics and CTCs10. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C,
Tibbe AGJ, Uhr JW, Terstappen LWMM: Tumor cells circulate in the
peripheral blood of all major carcinomas but not in healthy subjects or
patients with nonmalignant diseases. Clin Cancer Res 2004, 10:
6897e6904
11. Mohamed H, Murray M, Turner JN, Caggana M: Isolation of tumor
cells using size and deformation. J Chromatogr A 2009, 1216:
8289e8295
12. Tan S, Yobas L, Lee G, Ong C, Lim C: Microdevice for the isolation
and enumeration of cancer cells from blood. Biomed Microdevices
2009, 11:883e892
13. Zheng S, Lin H, Liu J-Q, Balic M, Datar R, Cote RJ, Tai Y-C:
Membrane microﬁlter device for selective capture, electrolysis and
genomic analysis of human circulating tumor cells. J Chromatogr A
2007, 1162:154e161
14. Yamada M, Nakashima M, Seki M: Pinched ﬂow fractionation:
continuous size separation of particles utilizing a laminar ﬂow proﬁle
in a pinched microchannel. Ann Chem 2004, 76:5465e5471
15. Carlo DD: Inertial microﬂuidics. Lab Chip 2009, 9:3038e3046
16. Bhagat AAS, Hou HW, Li LD, Lim CT, Han J: Pinched ﬂow coupled
shear-modulated inertial microﬂuidics for high-throughput rare blood
cell separation. Lab Chip 2011, 11:1870e1878
17. Becker FF, Wang XB, Huang Y, Pethig R, Vykoukal J, Gascoyne PR:
Separation of human breast cancer cells from blood by differential
dielectric afﬁnity. Proc Natl Acad Sci U S A 1995, 92:860e864
18. Gascoyne PRC, Noshari J, Anderson TJ, Becker FF: Isolation of rare
cells from cell mixtures by dielectrophoresis. Electrophoresis 2009, 30:
1388e1398
19. Davies J, Dawkes AC, Haymes AG, Roberts CJ, Sunderland RF,
Wilkins MJ, Davies MC, Tendler SJB, Jackson DE, Edwards JC: A
scanning tunneling microscopy comparison of passive antibody
adsorption and biotinylated antibody linkage to streptavidin on
microtiter wells. J Immunolog Meth 1994, 167:263e269
20. Spitznagel TM, Clark DS: Surface-density and orientation effects on
immobilized antibodies and antibody fragments. Biotechnology (NY)
1993, 11:825e829
21. Hughes AD, King MR: Use of naturally occurring halloysite nano-
tubes for enhanced capture of ﬂowing cells. Langmuir 2010, 26:
12155e12164
22. Wang S, Wang H, Jiao J, Chen K, Owens GE, Kamei K, Sun J,
Sherman DJ, Behrenbruch CP, Wu H, Tseng H: Three-dimensional
nanostructured substrates toward efﬁcient capture of circulating tumor
cells. Angew Chem Int Ed Engl 2009, 48:8970e8973
23. Wang S, Liu K, Liu J, Yu ZT-F, Xu X, Zhao L, Lee T, Lee EK,
Reiss J, Lee Y, Chung LWK, Huang J, Rettig M, Seligson D,
Duraiswamy KN, Shen CK, Tseung HR: Highly efﬁcient capture of
circulating tumor cells by using nanostructured silicon substrates with
integrated chaotic micromixers. Angew Chem Int Ed Engl 2011, 50:
3084e3088
24. Mittal S, Wong IY, Deen WM, Toner M: Antibody-functionalized
ﬂuid-permeable surfaces for rolling cell capture at high ﬂow rates.
Biophys J 2012, 102:721e730
25. Chen GD, Fachin F, Fernandez-Suarez M, Wardle BL, Toner M:
Nanoporous elements in microﬂuidics for multiscale manipulation of
bioparticles. Small 2011, 7:1061e1067
26. Liu C, Stakenborg T, Henry O, O’Sullivan C, Borgen E, Schirmer C,
Laddach N, Roeser T, Latta D, Ritzi-Lehnert M, Fermer C, van de
Flierdt J, Hauch S, Lagae L: Lab-on-a-Chip for the magnetic isolation
and analysis of circulating tumor cells. 15th International Conference
on Miniaturized Systems for Chemistry and Life Sciences (mTAS
2011). 2011 October 2-6, Seattle. WA. Chemical and Biological
Microsystems Society 2011, 1:344e346The Journal of Molecular Diagnostics - jmd.amjpathol.org27. Saliba A-E, Saias L, Psychari E, Minc N, Simon D, Bidard F-C,
Mathiot C, Pierga J-Y, Fraisier V, Salamero J, Saada V, Farace F,
Vielh P, Malaquin L, Viovy J-L: Microﬂuidic sorting and multimodal
typing of cancer cells in self-assembled magnetic arrays. Proc Natl
Acad Sci U S A 2010, 107:14524e14529
28. Dharmasiri U, Njoroge SK, Witek MA, Adebiyi MG, Kamande JW,
Hupert ML, Barany F, Soper SA: High-throughput selection, enu-
meration, electrokinetic manipulation, and molecular proﬁling of low-
abundance circulating tumor cells using a microﬂuidic system. Anal
Chem 2011, 83:2301e2309
29. Seal SH: A sieve for the isolation of cancer cells and other large cells
from the blood. Cancer 1964, 17:637e642
30. Tan SJ, Lakshmi RL, Chen P, Lim W-T, Yobas L, Lim CT: Versatile
label free biochip for the detection of circulating tumor cells from
peripheral blood in cancer patients. Biosens Bioelectron 2010, 26:
1701e1705
31. Takagi J, Yamada M, Yasuda M, Seki M: Continuous particle sepa-
ration in a microchannel having asymmetrically arranged multiple
branches. Lab Chip 2005, 5:778e784
32. Yamada M, Seki M: Hydrodynamic ﬁltration for on-chip particle
concentration and classiﬁcation utilizing microﬂuidics. Lab Chip 2005,
5:1233e1239
33. Mach AJ, Kim JH, Arshi A, Hur SC, Di Carlo D: Automated cellular
sample preparation using a Centrifuge-on-a-Chip. Lab Chip 2011, 11:
2827e2834
34. Hur SC, Mach AJ, Di Carlo D: High-throughput size-based rare cell
enrichment using microscale vortices. Biomicroﬂuidics 2011, 5:22206
35. Shim S, Gascoyne P, Noshari J, Hale KS: Dynamic physical properties
of dissociated tumor cells revealed by dielectrophoretic ﬁeld-ﬂow
fractionation. Integr Biol 2011, 3:850e862
36. Foote J, Eisen HN: Kinetic and afﬁnity limits on antibodies produced
during immune responses. Proc Natl Acad Sci U S A 1995, 92:
1254e1256
37. Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA,
Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP,
Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H,
Watson JC, Weiner LM, Meropol NJ: Isolation and characterization of
circulating tumor cells in patients with metastatic colorectal cancer.
Clin Colorectal Cancer 2006, 6:125e132
38. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L,
Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P,
Balis UJ, Tompkins RG, Haber DA, Toner M: Isolation of rare
circulating tumour cells in cancer patients by microchip technology.
Nature 2007, 450:1235e1239
39. Stott SL, Hsu C-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA,
Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP,
Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S,
Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA,
Toner M: Isolation of circulating tumor cells using a microvortex-
generating herringbone-chip. Proc Natl Acad Sci U S A 2010, 107:
18392e18397
40. Stroock AD, Dertinger SK, Whitesides GM, Ajdari A: Patterning ﬂows
using grooved surfaces. Anal Chem 2002, 74:5306e5312
41. Stroock AD, Dertinger SKW, Ajdari A, Mezíc I, Stone HA,
Whitesides GM: Chaotic mixer for microchannels. Science 2002, 295:
647e651
42. Smirnov DA, Merdek KD, Sprott KM, Skelley AM, Huang R, Tenney
D, Jiang C, Milutinovic A, Tims D, Dong Y, Cain J, Wolfe M,
Pierceall WE, Carney WP: A microﬂuidic system for the selection of
circulating tumor cells that utilizes both afﬁnity and size capture
technologies. Presented at the 103rd American Association of Cancer
Research Annual Meeting, AACR 2012 March 31-April 4, Chicago, IL157
